Px Wire January-March 2012, Vol. 5, No. 1

Px Wire is AVAC's quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue identifies ten key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic. This issue also covers Gilead Science’s submission to the FDA for a label change for TDF/FTC (brand name Truvada); the closure of the 1% tenofovir gel arm of the VOICE trial; new trials launched this quarter; the first meeting of Project ARM (Africa for Rectal Microbicides).